Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03484884 · ClinicalTrials.gov registry record
A Study of Optical Imaging With Light From Radiotracers in Cancer Patients
A clinical trial of Thyroid Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- 102
- Enrollment target
- 1
- Study location
NCT03484884: Active study of Thyroid Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03484884 is a study of Thyroid Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 102 participants, below the 280-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03484884, a study of Thyroid Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 102 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test Cerenkov luminescence imaging, which is a different way to take pictures of thyroid cancer and/or any tumors with (existing or suspected) nodal metastases in the neck, supraclavicular, axillary and/or inguinal region.
Primary Outcome
The primary objective is to explore the overall feasibility of clinical Cerenkov imaging on patients with any tumors with nodal metastases (existing or suspected) scheduled for routine clinical FDG PET or 131I therapy.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Cerenkov luminescence imaging.
Study Locations (1)
New York
- Memorial Sloan - Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2018-03-20 |
| Est. Completion | 2026-03 |
What the registry record for NCT03484884 still lists
NCT03484884 is an observational study that tracks outcomes without assigning an intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap, below the 280-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (64% lower).
The record links to 1 condition, with Thyroid Cancer appearing as the primary indexed condition, and to 1 intervention - of which Cerenkov luminescence imaging. is the first listed.
NCT03484884 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03484884 about?
NCT03484884 is a clinical study titled "A Study of Optical Imaging With Light From Radiotracers in Cancer Patients". The purpose of this study is to test Cerenkov luminescence imaging, which is a different way to take pictures of thyroid cancer and/or any tumors with (existing or suspected) nodal metastases in the neck, supraclavicular, axillary and/or inguinal region.
What is the current status of trial NCT03484884?
This trial is currently active not recruiting. The enrollment target is 102 participants. The study started on 2018-03-20. Estimated completion is 2026-03.
What conditions does trial NCT03484884 study?
This clinical trial studies the following conditions: Thyroid Cancer.
What interventions are being tested in trial NCT03484884?
The interventions under investigation include: Cerenkov luminescence imaging. (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03484884?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03484884 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03484884's enrollment target sits among peer trials
102 16th of 46 higher than 31 of 46 other Thyroid Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thyroid Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
RECRUITING · Phase 2
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
-
A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer
RECRUITING
-
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704662 · 102 participants · NA
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
- NCT04174742 · 102 participants
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
- NCT04275362 · 102 participants
Gait Analysis of a Lateral-Pivot Design Total Knee Replacement
- NCT04541082 · 102 participants · Phase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI